The novel TPM1 mutation V95A causing hypertrophic cardiomyopathy is associated with a mild cardiac phenotype but poor prognosis, with 13 deaths among 26 affected members.
Observational (n=26)
The novel TPM1 V95A mutation causes hypertrophic cardiomyopathy characterized by a mild morphological phenotype but a poor prognosis with high rates of sudden death, driven by abnormal calcium binding and myosin cycling.
BACKGROUND: We report hypertrophic cardiomyopathy (HCM) in a Spanish-American family caused by a novel alpha-tropomyosin (TPM1) mutation and examine the pathogenesis of the clinical disease by characterizing functional defects in the purified mutant protein. METHODS AND RESULTS: HCM was linked to the TPM1 gene (logarithm of the odds LOD score 3.17). Sequencing and restriction digestion analysis demonstrated a TPM1 mutation V95A that cosegregated with HCM. The mutation has been associated with 13 deaths in 26 affected members (11 sudden deaths and 2 related to heart failure), with a cumulative survival rate of 73+/-10% at the age of 40 years. Left ventricular wall thickness (mean 16+/-6 mm) and disease penetrance (53%) were similar to those for the ss-myosin mutations L908V and G256E previously associated with a benign prognosis. Left ventricular hypertrophy was milder than with the ss-myosin mutation R403Q, but the prognosis was similarly poor. With the use of recombinant tropomyosins, we identified several functional alterations at the protein level. The mutation caused a 40% to 50% increase in calcium affinity in regulated thin filament-myosin subfragment-1 (S1) MgATPase assays, a 20% decrease in MgATPase rates in the presence of saturating calcium, a 5% decrease in unloaded shortening velocity in in vitro motility assays, and no change in cooperative myosin S1 binding to regulated thin filaments. CONCLUSIONS: In contrast to other reported TPM1 mutations, V95A-associated HCM exhibits unusual features of mild phenotype but poor prognosis. Both myosin cycling and calcium binding to troponin are abnormal in the presence of the mutant tropomyosin. The genetic diagnosis afforded by this mutation will be valuable in the management of HCM.
Karibe et al. (Tue,) conducted a observational in Hypertrophic Cardiomyopathy (n=26). TPM1 mutation V95A vs. Other myosin mutations (L908V, G256E, R403Q) was evaluated on Cumulative survival rate at age 40 years. The novel TPM1 mutation V95A causing hypertrophic cardiomyopathy is associated with a mild cardiac phenotype but poor prognosis, with 13 deaths among 26 affected members.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: